Home > Search Results: Piperidines
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
14 p, 2.4 MB Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects / Baquero, Juan Miguel (Centro Nacional de Investigaciones Oncológicas) ; Benítez-Buelga, Carlos (Karolinska Institutet (Estocolm, Suècia)) ; Rajagopal, Varshni (Karolinska Institutet (Estocolm, Suècia)) ; Zhenjun, Zhao (Karolinska Institutet (Estocolm, Suècia)) ; Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Müller, Sarah (Karolinska Institutet (Estocolm, Suècia)) ; Hanna, Bishoy M. F. (Karolinska Institutet (Estocolm, Suècia)) ; Loseva, Olga (Karolinska Institutet (Estocolm, Suècia)) ; Wallner, Olov (Karolinska Institutet (Estocolm, Suècia)) ; Michel, Maurice (Karolinska Institutet (Estocolm, Suècia)) ; Rodriguez-Perales, Sandra (Grupo de Citogenética Molecular. Programa de Genética del Cáncer Humano. Centro Nacional de Investigaciones Oncológicas de España (Madrid)) ; Gad, Helge (The University of Sheffield) ; Visnes, Torkild (SINTEF Industry (Noruega)) ; Helleday, Thomas (The University of Sheffield) ; Benitez, Javier (Centro Nacional de Investigaciones Oncológicas) ; Osorio, Ana (Centro Nacional de Investigaciones Oncológicas) ; Universitat Autònoma de Barcelona
The most common oxidative DNA lesion is 8-oxoguanine which is mainly recognized and excised by the 8-oxoG DNA glycosylase 1 (OGG1), initiating the base excision repair (BER) pathway. Telomeres are particularly sensitive to oxidative stress (OS) which disrupts telomere homeostasis triggering genome instability. [...]
2021 - 10.1038/s41598-021-82917-7
Scientific reports, Vol. 11 Núm. 1 (december 2021) , p. 3490  
Detailed record - Creative Commons
2.
15 p, 664.9 KB Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study / Wierda, W. G. (University of Texas.) ; Allan, J. N. (Weill Cornell Medicine) ; Siddiqi, Tanya (City of Hope National Medical Center) ; Kipps, T. J. (UCSD. Moores Cancer Center) ; Opat, S. (Monash University) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Badoux, X. C. (Ministry of Health) ; Kuss, B. J. (Flinders University. Medical Centre) ; Jackson, Sharon (Middlemore Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Jacobs, R. M. D. (Levine Cancer Institute) ; Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ; Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ; Pak, Y. (Pharmacyclics LLC. AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ; Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ; Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ; Dean, James P (Pharmacyclics LLC. AbbVie Company) ; James, D. F. (Pharmacyclics LLC. AbbVie Company) ; Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ; Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ; Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865  
Detailed record - Creative Commons
3.
10 p, 290.8 KB Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer / Peters, S. (Lausanne University Hospital) ; Camidge, David Ross (University of Colorado) ; Shaw, A. T. (Massachusetts General Hospital (Boston)) ; Gadgeel, S. (University of Michigan) ; Ahn, Jin Seop (Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Kim, Dong-Wan (Seoul National University Hospital) ; Ou, S. H. I. (School of Medicine) ; Pérol, M. (Department of Medical Oncology. Léon Bérard Cancer Center) ; Dziadziuszko, R. (Department of Oncology and Radiotherapy. Medical University of Gdansk) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zeaiter, A. (F. Hoffmann-La Roche) ; Mitry, E. (F. Hoffmann-La Roche) ; Golding, S. (F. Hoffmann-La Roche) ; Balas, B. (F. Hoffmann-La Roche) ; Noe, J. (F. Hoffmann-La Roche) ; Morcos, P. N. (Roche Innovation Center) ; Mok, T. (State Key Laboratory of South China. Chinese University of Hong Kong)
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). [...]
2017 - 10.1056/NEJMoa1704795
The New England journal of medicine, Vol. 377 Núm. 9 (31 2017) , p. 829-838  
Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with